May 12, 2008
Toward Health Equality and Patient-Centeredness: Integrating Health Literacy, Disparities Reduction, and Quality Improvement
Institute of Medicine of the National Academies
Washington, D.C.
The Institute of Medicine's Forum on the Science of Health Care Quality Improvement and Implementation in collaboration with the Roundtable on Health Disparities and the Roundtable on Health Literacy will hold a public workshop on May 12, 2008.; This event is free and open to the public.
May 15, 2008
American Health Information Community Consumer Empowerment Workgroup Meeting
Office Of The National Coordinator for Health Information Technology
Washington, DC
The Workgroup will continue its discussion on how to encourage the widespread adoption of a personal health record that is easy-to-use, portable, longitudinal, affordable, and consumer-centered. The meeting will be available via Web cast.
May 15 - 16, 2008
Risk Communication Advisory Committee Meeting
Food and Drug Administration
Rockville, MD
On May 15, 2008, the committee will meet for presentations and discussion of direct-to-consumer (DTC) advertising, including how it relates to communicating to subsets of the general population, such as the elderly, children, and racial and ethnic minority communities, and increased access to health information and decreased health disparities for these populations. On May 16, 2008, the committee will discuss studying the appropriateness of including, in televised DTC ads, a statement encouraging consumers to report negative side effects of prescription drugs to MedWatch, as is currently required for print DTC prescription drug ads.
May 19, 2008
FDA/DIA Co-sponsored Conference on The Orphan Drug Act (ODA) at 25 Years: Retrospective and Future Views
Food and Drug Administration
Washington, DC
In celebration of the 25th anniversary of the Orphan Drug Act, FDA, industry and patient advocacy groups are coming together to discuss accomplishments, perspectives, globalization, and future challenges in the development of therapeutic drugs and devices for the treatment of rare diseases. Current updates on the processes, procedures, and resources to enable the successful movement of products for rare diseases from research to approval will be discussed. This will include information on Orphan Drug Designation applications, Humanitarian Use Device designation applications, and Orphan Products Grant applications as well as other regulatory components.
May 21, 2008
American Health Information Community Electronic Health Records Workgroup Meeting
Office Of The National Coordinator for Health Information Technology
Washington, DC
The Workgroup will continue its discussion on ways to achieve widespread adoption of certified EHRs, minimizing gaps in adoption among providers. The meeting will be available via Web cast.
May 21 - 22, 2008
National Committee on Vital and Health Statistics Meeting
Department of Health and Human Services
Washington, DC
At this meeting the Committee will hear presentations and hold discussions on several health data policy topics. On the first day the Committee will hear updates from the Department by the Data Council and the HHS Office of the National Coordinator (ONC). They will also discuss letters to the HHS Secretary on hospital surge capacity and e-prescribing standards and long term care. Later in the afternoon there will be an update on classification issues in healthcare terminology. On the morning of the second day the Committee will continue the discussions on the letters on surge capacity and e-prescribing standards. The remainder of the time will be spent discussing future agenda items and Committee administrative operations.
May 27, 2008
American Health Information Community Confidentiality, Privacy, and Security Workgroup Meeting
Office Of The National Coordinator for Health Information Technology
Washington, DC
The Workgroup Members will continue discussing and evaluating the confidentiality, privacy, and security protections and requirements for participants in electronic health information exchange environments. The meeting will be available via Web cast.
May 29, 2008
American Health Information Community Chronic Care Workgroup Meeting
Office Of The National Coordinator for Health Information Technology
Washington, DC
The workgroup will hear testimony on ways to use information technology to better coordinate care for patients with chronic conditions and will discuss this information in light of opportunities to better facilitate patient care coordination. The meeting will be available via Web cast.
May 30, 2008
Oncologic Drugs Advisory Committee Meeting
Food and Drug Administration
Chicago, IL
The committee will discuss the new drug application (NDA) 022-291, proposed trade name PROMACTA (eltrombopag olamine), by GlaxoSmithKline, proposed indication for the short-term treatment of previously-treated patients with chronic idiopathic thrombocytopenic purpura (ITP) to increase platelet counts and reduce or prevent bleeding.
May 30, 2008
Science Board Meeting
Food and Drug Administration
Gaithersburg, MD
The Science Board will hear about and discuss a subcommittee review of the National Center for Toxicological Research and Office of Regulatory Affairs. The Science Board will discuss keeping pace with technical and scientific evolutions in the fields of regulatory science. The Science Board will also hear about and discuss updates on a subcommittee review of the agency's science programs and infrastructure from the June 14, 2007, and December 3, 2007, Science Board meetings.
June 2 - 4, 2008
National Advisory Committee on Rural Health and Human Services Meeting
Health Resources and Services Administration
Chapel Hill, NC
Presentations on June 2nd will include: an overview of rural North Carolina; the three chosen Subcommittee topics of workforce and community development, at-risk children, and the medical home model; and an overview of the Tuesday, June 3rd site visits. On Wednesday, June 4th the Committee will break into Subcommittees for forty-five minutes and then the Committee will reconvene for a review of the site visits and development of action items. The Committee will conclude by drafting a letter to the Secretary and discussing the September meeting.
June 6, 2008
Advisory Committee to the Director Meeting
National Institutes of Health
Bethesda, MD
Among the topics proposed for discussion are: (1) NIH Director's Report; (2) NIH Director's Council of Public Representatives Liaison Report; (3) Peer Review; (4) Report from the Working Group on Participant and Data Protection for Gene-Wide Association Studies; and (5) Report from NIH Blue Ribbon Panel on the National Emerging Infectious Disease Lab at Boston University Medical Center.
June 6, 2008
National Advisory Council for Complementary and Alternative Medicine Meeting
National Center for Complementary Alternative Medicine
Bethesda, MD
The agenda includes opening remarks by the Director of the National Center for Complementary and Alternative Medicine, presentation of a new research initiative, and other business of the Council. The public comments session is scheduled from 3:30-4 p.m., but could change depending on the actual time spent on each agenda item. Each speaker will be permitted 5 minutes for their presentation. Interested individuals and representatives of organizations are requested to notify Dr. Martin H. Goldrosen, National Center for Complementary and Alternative Medicine, NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, Maryland, 20892, 301-594-2014, Fax: 301-480-9970. Letters of intent to present comments, along with a brief description of the organization represented, should be received no later than 5 p.m. on June 4, 2008. Only one representative of an organization may present oral comments.
June 10, 2008
National Advisory Council on Minority Health and Health Disparities Meeting
National Center on Minority Health and Health Disparities
Bethesda, MD
The agenda will include opening remarks, administrative matters, Director's report, NCMHD health disparities update, scientific program highlights, and other business of the Council.
June 17 - 18, 2008
National Cancer Advisory Board
National Cancer Institute
Bethesda, MD
The agenda includes a report from the NCI Director, ongoing and new business, reports of special initiatives, and scientific presentations. The meeting will be open to the public, with attendance limited to space available. Any interested person may file written comments with the committee by forwarding the statement to Paulette S. Gray, PhD, Executive Secretary, Director, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Rm. 8001, Bethesda, Md 20892, 301-496-5147, grayp@mail.nih.gov. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.
June 18 - 19, 2008
Scientific Advisory Committee on Alternative Toxicological Methods Meeting
National Institute of Environmental Health Sciences
Research Triangle Park, NC
The Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) advises the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), and the Director of the NIEHS and NTP regarding statutorily mandated duties of ICCVAM and activities of NICEATM. Preliminary agenda topics include: an overview of NICEATM-ICCVAM 5-Year Plan; NRC report: Toxicity Testing in the 21st Century; presentations from federal agencies on research, development, translation, and validation activities relevant to the NICEATM-ICCVAM Five-Year Plan; and nominations to ICCVAM. Persons registering to make oral comments are asked to do so through the online registration form and to send a copy of their statement to Dr. White at NTP Office of Liaison, Policy and Review, NIEHS, P.O. Box 12233, MD A3-01, Research Triangle Park, NC 27709; telephone: 919-541-9834 or e-mail: whiteld@niehs.nih.gov.
June 23 - 24, 2008
Board of Scientific Advisors
National Cancer Institute
Bethesda, MD
The agenda includes a report from the NCI Director, ongoing and new business, reports of Program Review Group(s), a budget presentation, reports of special initiatives, RFA and RFP concept reviews, and scientific presentations. The meeting will be open to the public, with attendance limited to space available. Any interested person may file written comments with the committee by forwarding the statement to Paulette S. Gray, PhD, Executive Secretary, Director, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Rm. 8001, Bethesda, Md 20892, 301-496-5147, grayp@mail.nih.gov. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.
June 25, 2008
Clinical Trials Advisory Committee Meeting
National Cancer Institute
Bethesda, MD
The agenda includes updates on the progress of the implementation of the Clinical Trials Working Group and the Translational Research Working Group reports. The meeting will be open to the public, with attendance limited to space available. Any interested person may file written comments with the committee by forwarding the statement to Sheila A. Prindiville, MD, Director, Coordinating Center for Clinical Trials, Office of the Director, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd., Suite 507, Bethesda, MD 20892, 301-451-5048, prindivs@mail.nih.gov. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.
July 1 - 2, 2008
Multi-site Clinical Trials and the National Cancer Institute Cooperative Group Program
Institute of Medicine of the National Academies
Washington, D.C.
The purpose of this workshop is to discuss the possibilities for improving the efficiency and effectiveness of phase III clinical trials as conducted by the Cooperative Groups Program.
|
